Biogen/CV Therapeutics CVT-124 target market will be diuretic-resistant hospitalized CHF patients.
Executive Summary
BIOGEN/CV THERAPEUTICS CVT-124 DEVELOPMENT WILL TARGET DIURETIC- RESISTANT hospitalized congestive heart failure patients, CV Therapeutics said in a recent public offering prospectus. The company estimates that one-quarter of the 875,000 patients hospitalized annually with a primary diagnosis of CHF exhibit resistance to diuretic treatments "due to excessive fluid reabsorption in the proximal tubule." CVT-124, the prospectus states, blocks "the adenosine A1 receptors in the proximal tubule that would ordinarily stimulate sodium reabsorption at that site."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth